On Monday, March 13th, the VA announced it is covering the Alzheimer’s drug lecanemab (Leqembi), with conditions of reimbursement – inclusion and exclusion criteria – that are consistent with but also go well beyond the FDA label.
VA Will Cover Alzheimer’s Disease Drug Lecanemab, Provided A Detailed Set Of Inclusion And Exclusion Criteria Are Met
